<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408185</url>
  </required_header>
  <id_info>
    <org_study_id>MagicBullet/COLPHAR</org_study_id>
    <nct_id>NCT02408185</nct_id>
  </id_info>
  <brief_title>Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients</brief_title>
  <acronym>COLPHAR</acronym>
  <official_title>Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients With Severe Infections for Dose Optimization Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II clinical trial, open-labelled, prospective and single-center study directed to
      obtain blood samples in experimental detailed conditions in order to compare and optimize the
      dose of colistin in critically ill patients suffering from infections on which the indication
      of colistin would be accepted according to normal local protocols for severe infections
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile; Cmax (maximum reach concentration)/ MIC( Minimum inhibitory concentration) &gt;10</measure>
    <time_frame>Day 1 and day 3 after treatment</time_frame>
    <description>Plasma concentration will be measured for pharmacokinetic and pharmacodynamic profile the samples were drawn at 60, 120, 180, 240, 360, and 480 min after the end of the loading dose infusion and in patients of the group B, two more samples are taken at 600 and 720 min after the loading dose. Main pharmacokinetic parameters will be Cmax (maximum reach concentration)/ MIC(Minimum inhibitory concentration)&gt;10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of drug adverse reactions</measure>
    <time_frame>21 days of follow-up</time_frame>
    <description>All study drug related adverse reactions will be gathered and communicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile (&quot;Monte-Carlo simulation&quot; (statistical methodology) with MIC (Minimum inhibitory concentration) 50 y MIC (Minimum inhibitory concentration) 90 from samples isolation)</measure>
    <time_frame>Day 1 and day 3 after treatment</time_frame>
    <description>&quot;Monte-Carlo simulation&quot; (statistical methodology) with MIC (Minimum inhibitory concentration) 50 y MIC (Minimum inhibitory concentration) 90 from samples isolation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Colistin 6 million units + 240mg/8h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose of 6 million units of colistin+ 240mg/8h maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colistin 6 million units + 360mg/12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading dose of 6 million units of colistin+ 360mg/12h maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin 6 million units + 240mg/8h</intervention_name>
    <description>240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)</description>
    <arm_group_label>Colistin 6 million units + 240mg/8h</arm_group_label>
    <other_name>colistin methanesulfonate (CMS)</other_name>
    <other_name>colistin base activity (CBA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colistin 6 million units + 360mg/12h</intervention_name>
    <description>360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)</description>
    <arm_group_label>Colistin 6 million units + 360mg/12h</arm_group_label>
    <other_name>colistin methanesulfonate (CMS)</other_name>
    <other_name>colistin base activity (CBA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 60 Kg of weigh

          -  Patients with directed treatment with colistin as the recommended antimicrobial
             treatment protocols in the hospital to treat some of the following serious infections
             caused by carbapenems resistant A. baumannii: (i) bacteremia; (ii) nosocomial
             pneumonia or (iii) infection of skin and soft tissue (cellulitis, abscesses or
             infected ulcers).

          -  Written informed consent form.

        Exclusion Criteria:

          -  Refractory shock or other illness with an expectative of life ˂ 48 hours after the
             recruitment;

          -  Patient declared not to resuscitation maneuvers;

          -  Suspicion or demonstration of endocarditis, osteomyelitis, or meningitis;

          -  Known hypersensitivity to polymyxins;

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Eugenia Pachón, BD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Biomedicina de Sevilla (IBIS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Miguel Cisneros, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infections</keyword>
  <keyword>multidrug resistant Gram negative bacteria (MDR-GNB)</keyword>
  <keyword>Skin infections</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Bacteriemia</keyword>
  <keyword>Nosocomial infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

